Product Description
AAV204, a novel adeno-associated virus (AAV) capsid from Abeona's in-licensed AIM™ capsid library, has previously been shown to facilitate transduction of both the inner and outer retina after intravitreal administration in mice and non-human primates. The purpose of the current study was to evaluate in non-human primates transduction levels in the macula and optic nerve following administration of AAV204 directly into the vitreous of the eye by para-retinal administration, a recently-developed method, which unlike subretinal administration does not create a retinal detachment. AAV204.GFP or AAV8.GFP were administered to four non-human primate eyes and green fluorescent protein (GFP) expression was monitored using scanning laser ophthalmoscopy (SLO), followed by immunohistochemistry analysis at 28 days post-injection. (Sourced from: https://investors.abeonatherapeutics.com/press-releases/detail/232/abeona-therapeutics-announces-aav204-a-novel-aav-capsid)
Mechanisms of Action: Gene Therapy, GFP
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Abeona
Company Location: Eastern America
Company CEO: Vishwas Seshadri
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Retinoschisis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|